B. Riley initiated coverage of RadNet (RDNT) with a Buy rating and $69 price target The company is the largest operator of outpatient radio imaging centers, the analyst tells investors in a research note. The firm says RadNet “is one of a kind of publicly traded companies” in the radiopharma value chain, which has a U.S.-centric operation that is relatively immune to tariffs. The company is a “one-stop shop,” offering both advanced imaging and routine imaging, contends Riley. It believes RadNet benefits from favorable industry trends of shifting imaging procedures from hospitals to non-hospital imaging centers and emerging novel radio imaging agents.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDNT:
- RadNet initiated with a Buy at B. Riley
- RadNet Secures $100 Million Loan for Growth
- RadNet’s Strategic Acquisition of See-Mode Technologies: A Boost to AI Capabilities and Revenue Growth
- Radnet’s Resilience and Strategic Growth: A Buy Recommendation Amidst Challenges and Opportunities
- RadNet’s Revenue Rises Amidst Challenges and Strategic Moves